GHRP-2vsIGF-1

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that binds to the GHS-R1a receptor on pituitary somatotrophs with high affinity, making it the second most potent GHRP for GH release after hexarelin. It activates the canonical Gq/11-PLC-IP3-calcium pathway, triggering robust GH vesicle exocytosis.

Beyond direct pituitary action, GHRP-2 modulates GH release at the hypothalamic level through two complementary mechanisms. It stimulates GHRH-producing neurons in the arcuate nucleus, amplifying the endogenous GHRH signal, and simultaneously suppresses somatostatin release from periventricular neurons, removing the inhibitory brake on GH secretion. This dual hypothalamic action explains why combining GHRP-2 with a GHRH analogue produces synergistic rather than merely additive GH release — the GHRP removes somatostatin inhibition while the GHRH analogue directly activates somatotrophs.

GHRP-2 occupies a middle ground in the GHRP family regarding selectivity. It produces moderate cortisol and prolactin elevation — less than hexarelin but more than ipamorelin. Its ghrelin-mimetic activity also stimulates appetite through hypothalamic NPY/AgRP neurons, though this effect is less pronounced than GHRP-6. Some research suggests GHRP-2 may have gastroprotective properties, with studies showing protection against ethanol-induced gastric mucosal damage in animal models. The peptide has been most extensively studied in Japan, where clinical trials evaluated its potential for treating GH deficiency, and it remains one of the best-characterized GHRPs in terms of pharmacology and dose-response relationships.

IGF-1 (Insulin-like Growth Factor 1) is a 70-amino-acid peptide hormone with approximately 50% structural homology to proinsulin. It is primarily produced by hepatocytes in response to growth hormone stimulation, though virtually all tissues produce IGF-1 locally for paracrine/autocrine signaling. Circulating IGF-1 is bound to six IGF binding proteins (IGFBP-1 through IGFBP-6), with approximately 80-90% bound to IGFBP-3 in a ternary complex with the acid-labile subunit (ALS). Only free, unbound IGF-1 (approximately 1-2% of total) can activate receptors.

IGF-1 binds to the IGF-1 receptor (IGF-1R), a heterotetrameric receptor tyrosine kinase structurally similar to the insulin receptor. Ligand binding triggers receptor autophosphorylation and recruitment of insulin receptor substrate (IRS) adaptor proteins, activating two major downstream cascades. The PI3K/Akt/mTOR pathway drives protein synthesis (through mTORC1 activation of S6K1 and inhibition of 4E-BP1), cell survival (through BAD phosphorylation and Bcl-2 family regulation), and glucose uptake (through GLUT4 translocation). The Ras/Raf/MEK/ERK pathway promotes cell proliferation, differentiation, and gene expression changes required for tissue growth.

In skeletal muscle, IGF-1's effects include both hypertrophy (enlargement of existing muscle fibers through increased protein synthesis) and hyperplasia (generation of new muscle cells through satellite cell activation and differentiation). Local muscle-derived IGF-1 isoforms (including the MGF splice variant) play a particularly important role in exercise-induced muscle adaptation. The very short half-life of free IGF-1 (10-20 minutes) means that therapeutic administration requires frequent dosing or modified forms (such as IGF-1 LR3 with its extended half-life). Native IGF-1 also binds the insulin receptor (with lower affinity), which contributes to its hypoglycemic effects — a significant clinical risk that requires careful glucose monitoring and administration with food.